RGLS REGULUS THERAPEUTICS INC Product Launches 8-K Filing 2025 - Study Results On March 27, 2025, Regulus Therapeutics announced positive results from the fourth cohort of its Phase 1b study of farabursen for treating autosomal dominant polycystic kidney disease, showing a mean growth rate of 0.05% in kidney volume compared to 2.58% in placebo patients. The study involved 26 subjects receiving 300 mg of farabursen every other week, demonstrating significant efficacy and a favorable safety profile.Get access to all SEC 8-K filings of the REGULUS THERAPEUTICS INC